EOLS
Evolus, Inc. NASDAQ Listed Feb 8, 2018$6.39
Mkt Cap $420.8M
52w Low $3.86
33.5% of range
52w High $11.42
50d MA $4.81
200d MA $6.10
P/E (TTM)
-6.7x
EV/EBITDA
-18.4x
P/B
—
Debt/Equity
-6.7x
ROE
223.5%
P/FCF
-9.4x
RSI (14)
—
ATR (14)
—
Beta
1.00
50d MA
$4.81
200d MA
$6.10
Avg Volume
1.1M
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
520 Newport Center Drive · Newport Beach, CA 92660 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | AMC | -0.14 | -0.05 | +67.4% | 5.58 | -2.3% | +14.2% | -0.8% | +1.1% | -0.5% | — | — |
| Mar 3, 2026 | AMC | 0.06 | 0.04 | -26.3% | 4.13 | +30.0% | +35.4% | +1.3% | -2.3% | -3.3% | -1.3% | — |
| Nov 5, 2025 | AMC | -0.19 | -0.14 | +26.3% | 6.81 | +12.9% | +5.4% | -8.6% | +7.5% | -0.9% | +4.4% | — |
| Aug 5, 2025 | AMC | -0.09 | -0.24 | -166.7% | 8.91 | -24.2% | -28.5% | -4.7% | -2.8% | -2.2% | +10.9% | — |
| May 7, 2025 | AMC | -0.10 | -0.18 | -80.0% | 11.76 | -5.2% | -14.2% | -2.9% | +1.8% | +1.5% | -1.4% | — |
| Mar 4, 2025 | AMC | 0.02 | 0.01 | -50.0% | 14.35 | +1.0% | -1.3% | -4.7% | +0.6% | -6.6% | +0.2% | — |
| Nov 6, 2024 | AMC | -0.08 | -0.19 | -137.5% | 16.81 | -9.2% | -15.0% | -4.3% | -4.1% | -5.2% | -1.5% | — |
| Jul 31, 2024 | AMC | -0.06 | -0.07 | -23.0% | 12.42 | +12.7% | +13.0% | -1.3% | -4.0% | -2.9% | -0.2% | — |
| May 7, 2024 | AMC | -0.07 | -0.13 | -85.7% | 13.42 | -2.0% | -1.2% | -1.0% | -2.9% | -1.1% | +1.3% | — |
| Mar 7, 2024 | AMC | -0.07 | -0.14 | -100.0% | 14.79 | -2.3% | -4.9% | -0.4% | +0.6% | -0.4% | +0.2% | — |
| Nov 7, 2023 | AMC | -0.22 | -0.19 | +13.6% | 8.08 | +14.5% | +8.2% | -5.1% | -3.5% | +1.5% | +4.1% | — |
| Aug 2, 2023 | AMC | -0.22 | -0.22 | +0.0% | 9.84 | +4.7% | +2.1% | -1.7% | -5.6% | +0.8% | -1.4% | — |
| May 9, 2023 | AMC | -0.13 | -0.17 | -30.8% | 9.07 | +5.0% | +16.0% | -2.1% | -0.4% | +0.6% | -5.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4 | BTIG | Maintains | Buy → Buy | — | $4.13 | $5.37 | +30.0% | +35.4% | +1.3% | -2.3% | -3.3% | -1.3% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.91 | $4.87 | -0.8% | -4.3% | -2.3% | -3.9% | +2.0% | -5.8% |
| Jan 22 | BTIG | Maintains | Buy → Buy | — | $4.90 | $4.94 | +0.8% | +3.7% | -3.1% | -2.0% | +2.7% | -3.0% |
| Jan 13 | Stifel | Maintains | Buy → Buy | — | $5.77 | $5.74 | -0.5% | -0.9% | -12.2% | -0.4% | +4.0% | -2.7% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.74 | $5.64 | -1.7% | -1.6% | +2.1% | -0.9% | -12.2% | -0.4% |
| Dec 24 | Needham | Maintains | Hold → Hold | — | $6.81 | $6.80 | -0.1% | +0.6% | +0.7% | -3.5% | +0.2% | -0.3% |
| Dec 2 | Mizuho | Maintains | Outperform → Outperform | — | $6.82 | $6.82 | +0.0% | -4.4% | +3.5% | +0.9% | +0.6% | +1.8% |
| Sep 8 | BTIG | Maintains | Buy → Buy | — | $7.66 | $7.61 | -0.7% | -0.7% | -2.9% | -0.5% | +2.2% | -4.3% |
| Aug 6 | Needham | Downgrade | Buy → Hold | — | $8.91 | $6.75 | -24.2% | -28.5% | -4.7% | -2.8% | -2.2% | +10.9% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.91 | $6.75 | -24.2% | -28.5% | -4.7% | -2.8% | -2.2% | +10.9% |
| Aug 6 | BTIG | Maintains | Buy → Buy | — | $8.91 | $6.75 | -24.2% | -28.5% | -4.7% | -2.8% | -2.2% | +10.9% |
| May 8 | Needham | Maintains | Buy → Buy | — | $11.76 | $11.15 | -5.2% | -14.2% | -2.9% | +1.8% | +1.5% | -1.4% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.37 | $9.91 | -4.4% | -9.3% | +1.4% | +7.7% | -0.4% | -1.2% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $9.36 | $9.13 | -2.5% | +10.8% | -9.3% | +1.4% | +7.7% | -0.4% |
| Mar 5 | Barclays | Maintains | Overweight → Overweight | — | $14.35 | $14.50 | +1.0% | -1.3% | -4.7% | +0.6% | -6.6% | +0.2% |
| Mar 5 | Needham | Maintains | Buy → Buy | — | $14.35 | $14.50 | +1.0% | -1.3% | -4.7% | +0.6% | -6.6% | +0.2% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.35 | $14.50 | +1.0% | -1.3% | -4.7% | +0.6% | -6.6% | +0.2% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.04 | $15.20 | +1.1% | -2.0% | +0.3% | +0.6% | -1.7% | -4.3% |
| Jan 27 | Barclays | Maintains | Overweight → Overweight | — | $14.23 | $14.23 | +0.0% | +3.7% | -3.6% | +2.3% | -2.4% | -1.7% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.48 | $13.68 | +1.5% | +4.8% | -0.8% | +1.5% | +3.7% | -3.6% |
| Jan 21 | Needham | Maintains | Buy → Buy | — | $10.51 | $12.98 | +23.5% | +28.3% | +4.8% | -0.8% | +1.5% | +3.7% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.81 | $15.26 | -9.2% | -15.0% | -4.3% | -4.1% | -5.2% | -1.5% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.32 | $16.41 | +0.6% | +2.6% | -2.0% | +0.4% | +1.9% | -15.0% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.14 | $17.32 | +1.1% | -0.5% | -4.2% | +0.9% | +0.1% | +1.6% |
| Sep 13 | Needham | Maintains | Buy → Buy | — | $16.46 | $16.80 | +2.1% | +6.3% | -4.1% | +0.7% | -4.0% | +1.4% |
| Sep 13 | Barclays | Maintains | Overweight → Overweight | — | $16.46 | $16.80 | +2.1% | +6.3% | -4.1% | +0.7% | -4.0% | +1.4% |
| Aug 1 | Needham | Maintains | Buy → Buy | — | $12.42 | $14.00 | +12.7% | +13.0% | -1.3% | -4.0% | -2.9% | -0.2% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.42 | $14.00 | +12.7% | +13.0% | -1.3% | -4.0% | -2.9% | -0.2% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.42 | $13.38 | -0.3% | -1.9% | -1.7% | -3.8% | +0.5% | +1.0% |
| May 8 | Needham | Maintains | Buy → Buy | — | $13.42 | $13.15 | -2.0% | -1.2% | -1.0% | -2.9% | -1.1% | +1.3% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.42 | $13.15 | -2.0% | -1.2% | -1.0% | -2.9% | -1.1% | +1.3% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $13.29 | $13.00 | -2.2% | -3.9% | -0.6% | -4.7% | -1.7% | +1.3% |
| Mar 8 | Needham | Maintains | Buy → Buy | — | $14.79 | $14.45 | -2.3% | -4.9% | -0.4% | +0.6% | -0.4% | +0.2% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.79 | $14.45 | -2.3% | -4.9% | -0.4% | +0.6% | -0.4% | +0.2% |
| Mar 8 | Stifel | Maintains | Buy → Buy | — | $14.79 | $14.45 | -2.3% | -4.9% | -0.4% | +0.6% | -0.4% | +0.2% |
| Mar 8 | Mizuho | Maintains | Buy → Buy | — | $14.79 | $14.45 | -2.3% | -4.9% | -0.4% | +0.6% | -0.4% | +0.2% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.83 | $14.83 | +0.0% | +0.5% | -1.1% | -1.2% | -3.2% | +4.8% |
| Jan 29 | Barclays | Upgrade | Equal Weight → Overweight | — | $11.94 | $12.68 | +6.2% | +12.8% | -3.7% | -2.2% | +2.8% | +3.3% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.43 | $11.00 | +5.5% | +19.7% | -5.1% | +0.1% | +2.0% | -2.8% |
| Dec 20 | Needham | Maintains | Buy → Buy | — | $9.84 | $10.14 | +3.0% | -1.6% | +3.1% | -0.2% | +0.7% | +1.2% |
| Aug 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.84 | $10.30 | +4.7% | +2.1% | -1.7% | -5.6% | +0.8% | -1.4% |
| Aug 3 | Needham | Maintains | Buy → Buy | — | $9.84 | $10.30 | +4.7% | +2.1% | -1.7% | -5.6% | +0.8% | -1.4% |
| Jul 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.13 | $10.26 | +1.3% | +0.0% | -1.1% | +1.5% | -3.2% | +2.1% |
| Jun 7 | Mizuho | Maintains | Buy → Buy | — | $8.74 | $8.78 | +0.5% | +0.1% | -1.9% | -3.0% | -1.1% | -1.9% |
| May 26 | Truist | Maintains | Buy → Buy | — | $8.98 | $9.06 | +0.9% | -2.2% | +2.5% | +0.6% | -4.2% | +2.3% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.07 | $9.52 | +5.0% | +16.0% | -2.1% | -0.4% | +0.6% | -5.9% |
| May 10 | Needham | Maintains | Buy → Buy | — | $9.07 | $9.52 | +5.0% | +16.0% | -2.1% | -0.4% | +0.6% | -5.9% |
| Jan 19 | SVB Leerink | Maintains | Outperform → Outperform | — | $9.99 | $10.17 | +1.8% | +5.3% | +5.0% | -0.2% | -2.2% | +2.3% |
| Jan 19 | Mizuho | Maintains | Buy → Buy | — | $9.99 | $10.17 | +1.8% | +5.3% | +5.0% | -0.2% | -2.2% | +2.3% |
| May 13 | Barclays | Upgrade | Underweight → Equal Weight | — | $12.04 | $12.07 | +0.2% | +9.5% | +4.1% | +1.6% | -11.5% | -2.3% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of Class II director Malik may signal leadership instability at EOLS, potentially affecting governance quality and investor confidence in the company's strategic direction.
Mar 13
8-K · 1.01
! Medium
Evolus, Inc. -- 8-K 1.01: Financing / Debt Agreement
Evolus secured $30 million in debt financing from Eclipse Business Capital LLC, providing liquidity for operations but increasing the company's leverage obligations.
Mar 3
Data updated apr 25, 2026 7:19am
· Source: massive.com